These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26478625)

  • 41. Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis.
    Marklund M; Aminde LN; Wanjau MN; Huang L; Awuor C; Steele L; Cobb LK; Veerman JL; Wu JH
    BMJ Glob Health; 2023 Oct; 8(10):. PubMed ID: 37848268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dietary Intake of
    Zupanič N; Hribar M; Hristov H; Lavriša Ž; Kušar A; Gregorič M; Blaznik U; Koroušić Seljak B; Golja P; Vidrih R; Žmitek K; Pravst I
    Nutrients; 2021 Jan; 13(1):. PubMed ID: 33445809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A trans world journey.
    Stender S; Dyerberg J; Bysted A; Leth T; Astrup A
    Atheroscler Suppl; 2006 May; 7(2):47-52. PubMed ID: 16713385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trans-Fatty Acids and Cardiovascular Disease: Urgent Need for Legislation.
    Wilczek MM; Olszewski R; Krupienicz A
    Cardiology; 2017; 138(4):254-258. PubMed ID: 28946140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of recommending certain replacement or alternative fats.
    Skeaff CM
    Eur J Clin Nutr; 2009 May; 63 Suppl 2():S34-49. PubMed ID: 19424217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trans fatty acids and coronary heart disease.
    Zaloga GP; Harvey KA; Stillwell W; Siddiqui R
    Nutr Clin Pract; 2006 Oct; 21(5):505-12. PubMed ID: 16998148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDA's proposed ban on trans fats: How do the costs and benefits stack up?
    Cohen JT
    Clin Ther; 2014 Mar; 36(3):322-7. PubMed ID: 24636817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trans-fatty acids in New Zealand patients with coronary artery disease.
    Benatar JR; Gladding P; White HD; Zeng I; Stewart RA
    Eur J Cardiovasc Prev Rehabil; 2011 Aug; 18(4):615-20. PubMed ID: 21450635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Trans fatty acids: effects on lipoprotein metabolism and cardiovascular risk].
    Attia-Skhiri N; Fournier N; Pourci ML; Paul JL
    Ann Biol Clin (Paris); 2009; 67(5):517-23. PubMed ID: 19789123
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.
    Rubinstein A; Colantonio L; Bardach A; Caporale J; Martí SG; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
    BMC Public Health; 2010 Oct; 10():627. PubMed ID: 20961456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dietary fats and coronary heart disease.
    Willett WC
    J Intern Med; 2012 Jul; 272(1):13-24. PubMed ID: 22583051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of trans fatty acids on health.
    Stender S; Dyerberg J
    Ann Nutr Metab; 2004; 48(2):61-6. PubMed ID: 14679314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective study of trans fatty acids in erythrocytes and risk of coronary heart disease.
    Sun Q; Ma J; Campos H; Hankinson SE; Manson JE; Stampfer MJ; Rexrode KM; Willett WC; Hu FB
    Circulation; 2007 Apr; 115(14):1858-65. PubMed ID: 17389261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study.
    Collins M; Mason H; O'Flaherty M; Guzman-Castillo M; Critchley J; Capewell S
    Value Health; 2014 Jul; 17(5):517-24. PubMed ID: 25128044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trans-fatty acids and nonlipid risk factors.
    Wallace SK; Mozaffarian D
    Curr Atheroscler Rep; 2009 Nov; 11(6):423-33. PubMed ID: 19852883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. trans fatty acids and systemic inflammation in heart failure.
    Mozaffarian D; Rimm EB; King IB; Lawler RL; McDonald GB; Levy WC
    Am J Clin Nutr; 2004 Dec; 80(6):1521-5. PubMed ID: 15585763
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intake of trans fatty acids from partially hydrogenated vegetable and fish oils and ruminant fat in relation to cancer risk.
    Laake I; Carlsen MH; Pedersen JI; Weiderpass E; Selmer R; Kirkhus B; Thune I; Veierød MB
    Int J Cancer; 2013 Mar; 132(6):1389-403. PubMed ID: 22821174
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of high and low trans-fatty acid consumers: analyses of UK National Diet and Nutrition Surveys before and after product reformulation.
    Hutchinson J; Rippin HL; Jewell J; Breda JJ; Cade JE
    Public Health Nutr; 2018 Feb; 21(3):465-479. PubMed ID: 29157320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trans fatty acid elimination policy in member states of the Eurasian Economic Union: Implementation challenges and capacity for enforcement.
    Demin A; Løge B; Zhiteneva O; Nishida C; Whiting S; Rippin H; Delles C; Karymbaeva S; Wickramasinghe K; Breda J
    J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1328-1337. PubMed ID: 32677762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of trans fatty acids in atherosclerosis, cardiovascular disease and infant development.
    Dalainas I; Ioannou HP
    Int Angiol; 2008 Apr; 27(2):146-56. PubMed ID: 18427401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.